Exavir Therapeutics Announces Entry Into a Litigation Settlement and License Agreement For Ultra-Long-Acting HIV Compounds With ViiV Healthcare
Exavir Therapeutics Receives $3M Award from NIH / NIAID to Advance Ultra-Long-Acting Integrase Inhibitor XVIR-110
GlaxoSmithKline PLC’s ViiV Healthcare Co. has sued Exavir Therapeutics Inc.’s alleging it licensing pact with the University of Nebraska on patents for compounds used in long-acting HIV therapies tortiously interferes with ViiV’s research collaboration agreement with the school and its business arm.
Ultra-long-acting plasma pharmacokinetics and biodistribution to tissues of interest demonstrated in three species Injections were well tolerated with no adverse findings in preliminary toxicology...
NEW YORK and OMAHA, Neb., May 23, 2022 (GLOBE NEWSWIRE) -- Exavir Therapeutics, a company dedicated to transforming the lives of people living with or at risk of acquiring HIV, today announced that...